

Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer

Mohamed A. Ahmed^{1,2}, Edgar Selzer³, Wolfgang Dörr^{3,4}, Gerd Jomrich⁵, Felix Harpain⁵, Gerd R. Silberhumer⁵, Leonhard Müllauer⁶, Klaus Holzmann¹, Bettina Grasl-Kraupp¹, Michael Grusch¹, Walter Berger¹, Brigitte Marian¹

¹Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria

²Radiation Biology Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Egypt

³Department of Radiotherapy and Radiobiology, Medical University of Vienna, Austria

⁴Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria

⁵Department of Surgery, Medical University Vienna, Austria

⁶Clinical Institute of Pathology, Medical University Vienna, Austria

Published: September 03, 2019

Copyright: Ahmed et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: While analyzing the same patient cohort for different markers, the authors realized a mistake in Table 2. The table reports on the correlation of radiation therapy response and FGFR4 immunoreactivity score. For both data sets, the stratification criteria were more stringent than mentioned in the table. However, the numerical results reported in the table were re-checked and found to be correct. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:69976–69990. <https://doi.org/10.18632/oncotarget.12099>

Table 2: FGFR4 expression and its correlation to clinicopathological characteristics and response of neoadjuvant chemoradiation treated rectal cancer patients. (a) *t*-test, (b) Chi square test.

	FGFR4 Expression		<i>p</i> -Value
	(negative - weak)*	(moderate - strong)*	
Median age, years	68.5 (26–79)	67.5 (34–90)	0.22 ^(a)
Sex, <i>n</i> (%)			
Women	5 (25)	7 (30.43)	0.74 ^(b)
Men	15 (75)	16 (69.56)	
Pre-treatment grading and staging			
Depth of invasion, <i>n</i> (%)			
T1, 2	2 (10)	1 (4.35)	0.59 ^(b)
T3, 4	18 (90)	22 (95.65)	
Lymph node metastasis, <i>n</i> (%)			
N0	8 (40)	5 (21.74)	0.31 ^(b)
N1, 2	12 (60)	18 (78.26)	
TNM stage, <i>n</i> (%)			
Stage I, II	8 (40)	5 (21.74)	0.31 ^(b)
Stage III	12 (60)	18 (78.26)	
Post-treatment grading and staging			
Depth of invasion, <i>n</i> (%)			
ypTX, 1, 2	11 (55)	10 (43.48)	0.54 ^(b)
ypT3, 4	9 (45)	13 (56.52)	
Lymph node metastasis, <i>n</i> (%)			
ypN0	16 (80)	14 (60.86)	0.2 ^(b)
ypN1, 2	4 (20)	9 (39.13)	
TNM stage, <i>n</i> (%)			
Stage 0	3 (15)	1 (4.35)	0.25 ^(b)
Stage I, II	13 (65)	13 (56.52)	
Stage III	4 (20)	9 (39.13)	
Therapy response **			
Strong response (3-4)	11 (55)	5 (21.74)	0.03 ^{(b)*}
Weak or no response (0-2)	9 (45)	18 (78.26)	

*The classification was done according to IRS: negative-weak (0-2); moderate-strong (3-12)

**Response was determined according to the criteria of Dworak et al. [23].